11/06/2018
Newsletters of Interest
A Few Articles You Won’t Want to Miss:
- Submit your precertification clinical information online
- Clinical payment and coding policy changes
- Our office manual keeps you informed
- Don’t let your network status change — complete your FDR attestation today
- Changes to commercial drug lists begin on January 1, 2019
And Much More….SEPTEMBER Mid-America Region Qtly Issue Available HERE
A Few Articles You Won’t Want to Miss:
- Blue Care Network will continue to offer 19 products for individual marketplace in 2019
- We’ve made improvements to Provider Inquiry
- Reminder: Starting Oct. 1, additional specialty medications required authorization for BCN AdvantageSM members
- BCN Advantage initiating step therapy to certain Part B specialty drugs on the prior authorization program beginning in January
- Specialty pharmacy program helps you care for your patients
And Much More…NOVEMBER/DECEMBER Bi-Monthly Issue Available HERE
Current Issue Available HERE
Current Issue Available HERE (once on the site, choose NEWS on the left side)
A Few Articles You Won’t Want to Miss:
- Complete 2018 Compliance Training Today
- Note Important Information for Dual-eligible Benefit Coordination
- Learn About the Humana Medicare Advantage Peer-to-Peer Review and Provider Dispute Processes
- New and Revised Pharmacy and Medical Coverage Policies Available
And Much More…Latest Issue Available HERE
A Few Articles You Won’t Want to Miss:
- Front & Center
- Billing for Intravenous and Subcutaneous Immune Globulin and Remicade®
- Prescription Drug List Updates
- UnitedHealthcare Commercial and UnitedHealthcare Community Plan Outpatient Injectable Cancer Therapy Authorization Program Update
- UnitedHealthcare Commercial
- Peer Comparison Reports Available in November 2018
- UnitedHealthcare Reimbursement Policies
- Update on Injection and Infusion Services Policy
And Much More…NOVEMBER Monthly Issue Available HERE
Oncology Related Articles You Won’t Want to Miss:
Medical Policy Updates
Updated:
- Apheresis - Effective Nov. 1, 2018
Revised:
- Genetic Testing for Hereditary Cancer - Effective Dec. 1, 2018
Medical Benefit Drug Policy Updates
Revised:
- Clotting Factors and Coagulant Blood Products - Effective Nov. 1, 2018
- Denosumab (Prolia® & Xgeva®) - Effective Nov. 1, 2018
- Immune Globulin (IVIG and SCIG) - Effective Nov. 1, 2018
- Ocrevus™ (Ocrelizumab) - Effective Nov. 1, 2018
- White Blood Cell Colony Stimulating Factors - Effective Nov. 1, 2018
Utilization Review Guideline (URG) Updates
New:
- Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) Scan - Site of Care - Effective Jan. 1, 2019
NOVEMBER Monthly Issue Available HERE